Adaptimmune Therapeutics Plc - ADR Stock, NASDAQ:ADAP
60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RX
Number of Employees: 462
Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.